Relationship between insulin resistance and some coagulation and fibrinolytic parameters in patients with metabolic syndrome

Laboratory Hematology

Volumn 14, Issue 1, 2008, Pages 1-6

  Ragab, Amany ^a   Abousamra, Nashwa Khayrat ^a   Higazy, Asmaa ^a   Saleh, Omayma ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Antithrombin III; Fibrinolysis; Tissue plasminogen activator; Von Willebrand factor antigen

Indexed keywords

ANTITHROMBIN III; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR; FIBRINOLYTIC AGENT;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; METABOLIC SYNDROME X; OBESITY; WAIST CIRCUMFERENCE; BLOOD; METABOLISM; MIDDLE AGED; VASCULAR ENDOTHELIUM;

ADULT; BLOOD COAGULATION FACTORS; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY;

EID: 68849127551     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.07017     Document Type: Article

References (32)

1. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly. 2002;132:241-252.
2. Jensen R. Hemostasis and the metabolic syndrome. Clin Hemostasis Rev. 2003;17:1-6.
3. Roman G, Hansu N. Metabolic syndrome - new insights into a growing entity. Rom J Intern Med. 2004;42:257-266.
4. Stassen JM, Arnout J, Deckmyn H. The haemostatic system. Curr Med Chem. 2004;11:2245-2260.
5. Thompson MA, Kienast G, Pyke S, Haverkate F. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
6. Ambrose JA, Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med. 1996;156:1382-1394.
7. Deloughery TG. Coagulation abnormalities and cardiovascular disease. Curr Opin Lipidol. 1999;10:443-448.
8. Rossi Ml, Merlini PA, Ardessino D. Laboratory markers of hypercoagulability. Ital Heart J. 2002;2:490-494.
9. Meade TW, Mellows S, Brozovic M, Miller GJ. Haemostatic function and ischemic heart disease. Lancet. 1985;2533-537.
10. Mertens I, Van Gaal LF. Obesity, haemostasis and fibrinolytic system. Obes Rev. 2002;3:85-101.
11. Executive summary of the third report of the National Cholesterol Education Program (NCEP), expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
12. Freir BM, Ashby JP, Nairn IM, Bairs JD. Plasma insulin, C-peptide and glucagon concentrations in patients with insulin dependent diabetes treated with chloropropamide. Diab Metab. 1981;7:45-49.
13. Temple RC, Clark PM, Hales CN. Measurement of insulin secretion in type 2 diabetes: problems and pitfalls. Diabet Med. 1992;9:503-512.
14. Kankle BA. Laboratory evaluation of von Willebrand disease. Clin Chem. 1995;41:489-490.
15. Griffin JH, Evatt B, Widman C. Anticoagulant protein C pathway is defective in the majority of thrombophilic patients. Blood. 1993;82:1989-1993.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
17. Juhan-Vague I, Alessi M, Vague P. Inreasedplasma PAI-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
18. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am. 2004;33:431-453.
19. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active t-PA and t-PA/PAI-1 complex in plasma. Blood. 1990;76:930-937.
20. Takanachi K, Inukai T. Insulin resistance and changes in blood coagulation fibrinolysis system after a glucose clamp technique in patients with type 2 diabetes. J Med. 2000;31:45-62.
21. Agewall S, Bokemark L, Wikstrand J, Lindahl A, Fagerbeg B. Insulin sensitivity and haemostatic factors in clinically healthy 58 years old men. Thromb Haemost. 2000;84:571-575.
22. Freeman MS. Mansfeild MW, Barret JH, Grant PJ. Insulin resistance: an atherothrombotic syndrome. The Leeds family study. Throb Haemost. 2000;89:161-168.
23. Kain K, Catto AJ, Grant PJ. Associations between insulin resistance and thrombotic risk factors in high-risk south Asian subjects. Diabet Med. 2000;20:651-655.
24. Richard S, Seigneur M, Blann A, Adams R. Vascular endothelial lesion in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1996;18:955-959.
25. Kessler L, Weissel ML, Attali P, Mossard JM. Von Willebrand factor in diabetic angiopathy. Diabetes Metab. 1998;24:327-336.
26. Jager A, Van Hinsbergh VW, Kostence PJ, Emeiss JJ. Von Willebrand factor, C reactive protein and 5-year mortality in diabetic and non-diabetic subjects. The Hoorn study. Arterioscler Thromb Vasc Biol. 1999;19:3071-3078.
27. Marques-Vidal P, Mazoyer E, Bongard V, Gourdy P. Prevalence of insulin resistance syndrome in southeastern France and its relationship with inflammatory and haemostatic markers. Diabetes Care. 2002;25:1371-1377.
28. Meigs JB, Mittleman MA, Nathan DM, Tofler GH. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283:221-228.
29. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002;87:3871-3875.
30. Bonora E, Tarcher G, Alberiche M, Bonnadonna R. Homeostsis model assessment mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 2000;23:57-63.
31. Mathews DR, Hosker JP, Rudenski AS, Naylor BA. Homeostasis model assessment: insulin resistance and beta cell function from fasting glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
32. Mennen LI, Balkau B, Charles MA. Gender differences in the relation between fibrinogen, t-PA antigen and markers of insulin resistance: effects of smoking. Thromb Haemost. 1999;82:1106-1111.